Please fill out this
form carefully:
- Fields marked with (*) are required.
- Characters other than English
letters, numbers or punctuation cannot be accepted by this
website.
POLICY STATEMENT
The International Academy of
Cardiology requires that audiences at the Academy's educational
programs be informed of a presenter's (moderators, speakers,
faculty, authors and contributors) academic and professional
affiliations, as well as other commercial relationships relevant
to the content of the material that is presented.
The policy allows the listener/attendee to be fully informed in
evaluating the information being presented.
The situations may include, but are not limited to
1) stock options or bond holdings in a for-profit corporation or
self-directed pension plan, 2) research grants, 3) employment
(full or part time), 4) ownership or partnership, 5) consulting
fees or other remuneration received by the presenter or his/her
immediate family, including support that may be provided to
attend the educational meeting, 6) nonremunerative positions of
influence such as officer, board member, trustee, or public
spokesperson. The disclosure will be shown as an indication (by
an *) for those presenters who have stated that a
relationship(s) exists relevant to the topic(s) being discussed.
Indicate any author(s) who has a
possible conflict of interest (see policy statement) by an
asterisk (*) next to that author(s) name in the heading of the
abstract.
|
|
PRESENTING AUTHOR'S PERSONAL DETAILS: |
| Family
name / Surname:(*) |
|
| First name
and middle initial(s):(*) |
|
| Title: |
|
| Mailing
Address |
|
Position:
complete this field only if
it is part of your mailing address |
|
Institution/Organization:
complete this field only if
it is part of your mailing address
|
|
Department:
complete this field only if
it is part of your mailing address
|
|
| Address:(*) |
|
| |
|
| City:(*) |
|
| State: |
|
| Country:(*) |
|
| Postal
code:(*) |
|
Work Phone (office
hours):
(*)
Country code/city code/number |
|
Home Phone
Country code/city code/number |
|
Fax:
Country code/city
code/number |
|
| E-mail
address:(*) |
|
| |
|
|
PREFERRED PRESENTATION TYPE (*) |
| |
|
Oral presentation |
|
Poster presentation |
|
Oral / Poster presentation |
| |
| For invited faculty
members only: |
|
This is the abstract of my invited presentation
|
| |
| AUTHORS
(*) |
|
| |
- Please list all authors in the
order they should appear in the publication.
- In the affiliation field
please enter the number
corresponding to the city and country listed above (e.g.: 1).
- Please choose only ONE
presenting author.
|
|
|
|
AUTHOR AFFILIATION
(*) |
Please list
ALL author(s) institution affiliations, in order to refer to
them by their number later (see below).
The authors must also include the following:
Institution, City, State, Country (i.e.,
Columbia University, New York, NY, USA)
|
| |
|
|
| |
|
ABSTRACT CATEGORY(*) |
| Select one category,
under which your abstract will be reviewed: |
-
Molecular cardiology, Basic
research
- Vascular biology, Basic
research
- Pharmacologic modulation
of vascular-endothelial function
- Genetic determinants of
coronary heart disease/cardiomyopathies
- Gene transfer and therapy
- Biochemical markers of
acute ischemia
- Contrast echocardiography
- Pharmacologic stress
testing - Echocardiography
- Echocardiography: TEE and
3-D
- Nuclear Cardiology
- PET/MRI/CT
- Other diagnostic methods:
Percutaneous coronary angioscopy / intravascular
ultrasound imaging /intracoronary flow, doppler
measurements
- The plaque and acute
coronary syndromes
- Myocardial stunning,
Hibernation and preconditioning
- Acute myocardial
infarction: thrombolysis and reperfusion
- Angioplasty therapy for
acute MI
- Stents: new
devices/optimal application/multiple stents
- Antithrombotic and
antiplatelet adjunctive therapy for PTCA
- Blockade of tissue
proliferation after coronary interventions
- Restenosis - use of
ionizing radiation
- Nitrates, beta blockers,
calcium entry blockers and ACE inhibition drugs for
ischemic heart disease
- Left ventricular
remodeling after MI
- Secondary prevention,
prognosis, risk stratification, cardiac rehab
- Modification of
lipoproteins and coronary disease
- Hypertension, basic and
clinical
- Diabetes mellitus,
obesity, insulin and atherosclerosis
- Primary prevention of
coronary artery disease in the healthy adult and children
- Hormone therapy in
postmenopausal women
- Natriuretic peptides,
endothelin: role in heart failure
- Neurohumoral, immunologic
and cytokine aspects of heart failure
- Nitric oxide and nitric
oxide synthase in heart failure
- Myocyte and receptor
abnormalities in heart failure
- Dilated cardiomyopathy:
various etiologies
- Left ventricular
hypertrophy and hypertrophic cardiomyopathy
- Role of the pericardium -
basic and clinical
- Pulmonary circulation
aspects, pulmonary hypertension
- Predictors and markers of
heart failure outcome
- Exercise physiology in
heart failure
- Renal aspects - diuretics
- Digoxin and other new
inotropic agents in heart failure
- ACE inhibitors and
Angiotensin-ll receptor blockers
- Organic nitrates-their
role in heart failure management
- Beta-blockers and beta-adrenergic
receptors in heart failure
- Calcium channel blockers
and promoters in heart failure
- Arrhythmias and
antiarrhythmic drug therapy - basic and clinical
- Sudden death
- Electrophysiologic
techniques of mapping and radiofrequency ablation
- Internal defibrillation/implantable
antiarrhythmic devices/pacing
- Pediatric cardiology and
cardiac surgery/congenital heart disease
- Angioplasty or surgery for
multivessel coronary artery disease
- New approaches to surgical
revascularization: minimally invasive surgery, TMLR
- Valvular heart
disease/Heart valve surgery-adult
- Mechanical support left
ventricular assist devices
- Surgery for LV dysfunction
- Cardiac transplantation
- Practice guidelines, cost
containment
- Computers in cardiology
- Miscellaneous
|
|
Please select: |
| |
| |
|
ABSTRACT TITLE (*)
Please enter the title in UPPERCASE: |
|
|
| |
| |
|
Abstract Body: (*) |
Please note:
- Symbols, Sub and Super
Script cannot be used in
this form. Symbols may be written in full (e.g. alpha,
beta).
- Characters other than
English letters, numbers or punctuation
cannot be accepted by this website.
- The abstract text should
not exceed 250 words.
|
|
| |
PLEASE NOTE: After
submitting abstract, you will see an
on-screen message "...your registration has been received"
and a reference number will be given to you.
This indicates your abstract has entered the system for
processing.
|
Please press the
"Submit" button ONCE only.
|
|